Halsey Associates Inc. CT Acquires New Stake in Edwards Lifesciences Corp (EW)

Halsey Associates Inc. CT acquired a new stake in shares of Edwards Lifesciences Corp (NYSE:EW) in the second quarter, HoldingsChannel reports. The firm acquired 4,691 shares of the medical research company’s stock, valued at approximately $683,000.

Other institutional investors have also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its position in Edwards Lifesciences by 3.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 794,667 shares of the medical research company’s stock worth $115,680,000 after buying an additional 26,346 shares in the last quarter. Summit Global Investments purchased a new stake in Edwards Lifesciences in the second quarter worth about $2,923,000. HighPoint Advisor Group LLC increased its position in Edwards Lifesciences by 38.0% in the first quarter. HighPoint Advisor Group LLC now owns 2,897 shares of the medical research company’s stock worth $414,000 after buying an additional 798 shares in the last quarter. Fulcrum Capital LLC purchased a new stake in Edwards Lifesciences in the second quarter worth about $2,920,000. Finally, CIBC Private Wealth Group LLC increased its position in Edwards Lifesciences by 7.2% in the second quarter. CIBC Private Wealth Group LLC now owns 995,781 shares of the medical research company’s stock worth $144,956,000 after buying an additional 66,544 shares in the last quarter. Institutional investors own 82.11% of the company’s stock.

In related news, VP Donald E. Bobo, Jr. sold 5,500 shares of the stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $144.16, for a total transaction of $792,880.00. Following the completion of the transaction, the vice president now directly owns 25,490 shares of the company’s stock, valued at $3,674,638.40. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Huimin Wang sold 3,800 shares of the stock in a transaction that occurred on Thursday, July 5th. The shares were sold at an average price of $146.60, for a total value of $557,080.00. The disclosure for this sale can be found here. Insiders have sold 177,511 shares of company stock valued at $25,420,691 in the last quarter. 1.84% of the stock is currently owned by company insiders.

A number of brokerages have commented on EW. Zacks Investment Research cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Monday, July 16th. Citigroup upped their price target on Edwards Lifesciences from $115.00 to $118.00 and gave the stock a “sell” rating in a research report on Tuesday, July 31st. SunTrust Banks reduced their price target on Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a research report on Friday, August 10th. Raymond James began coverage on Edwards Lifesciences in a research report on Thursday, May 31st. They issued an “outperform” rating and a $152.00 price target for the company. Finally, ValuEngine cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, June 6th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the company. Edwards Lifesciences presently has a consensus rating of “Buy” and an average target price of $152.45.

NYSE:EW opened at $147.99 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47. Edwards Lifesciences Corp has a 12-month low of $100.20 and a 12-month high of $156.87. The stock has a market cap of $30.34 billion, a P/E ratio of 38.94, a price-to-earnings-growth ratio of 2.00 and a beta of 0.57.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The firm had revenue of $972.00 million during the quarter, compared to analysts’ expectations of $968.32 million. During the same quarter last year, the business posted $1.08 earnings per share. The firm’s revenue was up 10.0% on a year-over-year basis. research analysts anticipate that Edwards Lifesciences Corp will post 4.67 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: Why Dividend Stocks May Be Right for You

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply